Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent
7 February 2022. Related: Antiretrovirals.
Antiretrovirals
Selected islatravir studies stop enrolment: further complications with important investigational drugs
20 December 2021. Related: Antiretrovirals.
FDA further limit use of islatravir in ongoing studies
20 December 2021. Related: Antiretrovirals.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks
30 November 2021. Related: Conference reports, Antiretrovirals.
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
30 November 2021. Related: Conference reports, Antiretrovirals.
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales
30 November 2021. Related: Antiretrovirals, Treatment access.
MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring
30 November 2021. Related: Antiretrovirals.
NHS Scotland approves long-acting cabotegravir and rilpivirine injections
31 October 2021. Related: Antiretrovirals.
Lenacapavir submitted to EMA for MDR HIV
17 September 2021. Related: Antiretrovirals.
Pipeline report 2021: HIV drugs in development
17 September 2021. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide
1 August 2021. Related: Conference reports, Antiretrovirals.
Lenacapavir submitted to FDA as long-acting treatment for MDR HIV
1 July 2021. Related: Antiretrovirals.
CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP
1 April 2021. Related: Conference reports, Antiretrovirals.
Gilead and Merck/MSD to collaborate on long-acting HIV combination of lenacapavir and islatravir
1 April 2021. Related: Antiretrovirals.
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
12 March 2021. Related: Conference reports, Antiretrovirals.
US FDA approves long-acting injectable HIV treatment: monthly dosing
22 January 2021. Related: Antiretrovirals.
Long-acting injectable HIV treatment approved in the EU: includes two-monthly dosing
22 January 2021. Related: Antiretrovirals.
Fostemsavir approved in the EU (Rukobia): NICE deferred in the UK
22 January 2021. Related: Antiretrovirals.
EU approves dolutegravir 5 mg dispersible for children older than four weeks
9 December 2020. Related: Antiretrovirals, Paediatric care.
New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year
9 December 2020. Related: Antiretrovirals, Treatment access, Paediatric care.
New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet
11 November 2020. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
EMA issues positive opinion to approve cabotegravir LA/rilpivirine LA injections (Vocabria/Rekambys) as new HIV treatment
11 November 2020. Related: Antiretrovirals.
Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes
14 October 2020. Related: Conference reports, Antiretrovirals.
Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg
14 October 2020. Related: Conference reports, Antiretrovirals.
Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing
28 August 2020. Related: Conference reports, Antiretrovirals.
US FDA approves dolutegravir/lamivudine (Dovato) as switch option
28 August 2020. Related: Antiretrovirals.
EMA extends indication for darunavir/r to include adolescents >12 years
28 August 2020. Related: Antiretrovirals.
ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva, Vocabria) to FDA for approval
28 August 2020. Related: Antiretrovirals.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau
22 July 2020. Related: Conference reports, Antiretrovirals.
FDA approves fostemsavir (Rukobia) for multidrug resistant HIV in the US
22 July 2020. Related: Antiretrovirals.
FDA approves dolutegravir formulations to treat infants and young children
26 June 2020. Related: Antiretrovirals, Paediatric care.
Fit for purpose: antiretroviral treatment optimisation March 2020
12 March 2020. Related: Special reports, Supplements, Fit for purpose, Antiretrovirals.
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
12 March 2020. Related: Conference reports, Antiretrovirals.
Long-acting cabotegravir and rilpivirine: similar results in women and men
24 February 2020. Related: Conference reports, Antiretrovirals, Women's health.
FDA decision on long-acting cabotegravir/rilpivirine (Cabenuva, Vocabria) injections delayed due to scale-up manufacturing problems
29 January 2020. Related: Antiretrovirals.
Fostemsavir submitted to EMA for treating multidrug resistant HIV
29 January 2020. Related: Antiretrovirals.
Gilead announces licensing agreement for Rockefeller University bNAbs
29 January 2020. Related: Antiretrovirals.
Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV
13 December 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine as dual ART
13 December 2019. Related: Conference reports, Antiretrovirals.
Weight changes with doravirine-based first line therapy
13 December 2019. Related: Conference reports, Antiretrovirals, Side effects.
Doravirine approved by NHS England as single NNRTI and as part of FDC with 3TC/TDF
13 December 2019. Related: Antiretrovirals.
Fostemsavir submitted to US FDA for multidrug resistant HIV
13 December 2019. Related: Antiretrovirals.
Paediatric dispersible formulation of dolutegravir submitted to EMA and FDA
13 December 2019. Related: Antiretrovirals.
Ibalizumab approved in the EU
15 November 2019. Related: Antiretrovirals.
HIV suppression and safety with ibalizumab at 48 weeks in expanded access
18 October 2019. Related: Conference reports, Antiretrovirals.
Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
18 October 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
18 October 2019. Related: Conference reports, Antiretrovirals.
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Possible higher diabetes risk with raltegravir or PIs than NNRTIs
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Dual dolutegravir/lamivudine submitted to US FDA as switch option
18 October 2019. Related: Antiretrovirals.
Scotland approves dual therapy with dolutegravir/lamivudine (Dovato)
30 September 2019. Related: Antiretrovirals, Treatment access.
FDA expands indication for doravirine in the US as switch option
30 September 2019. Related: Antiretrovirals.
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
23 August 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA
23 August 2019. Related: Antiretrovirals.
First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results
24 July 2019. Related: Conference reports, Antiretrovirals.
Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy
24 July 2019. Related: Conference reports, Antiretrovirals.
Fostemsavir: 96-week follow-up in people with multi-drug resistance
24 July 2019. Related: Conference reports, Antiretrovirals.